Satellos Bioscience (NASDAQ:MSLE) Now Covered by Craig Hallum

Stock analysts at Craig Hallum began coverage on shares of Satellos Bioscience (NASDAQ:MSLE) in a report issued on Thursday, Benzinga reports. The firm set a “buy” rating and a $24.00 price target on the stock. Craig Hallum’s price target would suggest a potential upside of 225.87% from the company’s current price.

Several other equities analysts also recently issued reports on the stock. Wells Fargo & Company set a $18.00 price objective on shares of Satellos Bioscience in a report on Thursday, July 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Satellos Bioscience in a research note on Friday, August 7th. Finally, HC Wainwright restated a “buy” rating and issued a $18.00 price target on shares of Satellos Bioscience in a research note on Monday, August 17th. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $20.60.

Satellos Bioscience Stock Down 3.5%

Shares of NASDAQ:MSLE traded down $0.27 during trading on Thursday, hitting $7.37. 23,735 shares of the stock traded hands, compared to its average volume of 56,386. The company has a market cap of $156.29 million, a price-to-earnings ratio of -3.84 and a beta of 1.51. The company has a fifty day moving average price of $9.33 and a two-hundred day moving average price of $7.99. Satellos Bioscience has a 52-week low of $5.30 and a 52-week high of $13.39.

Satellos Bioscience (NASDAQ:MSLE) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.18). On average, equities research analysts predict that Satellos Bioscience will post -1.86 EPS for the current fiscal year.

Institutional Investors Weigh In On Satellos Bioscience

A hedge fund recently raised its stake in Satellos Bioscience stock. Stonepine Capital Management LLC increased its stake in shares of Satellos Bioscience Inc. (NASDAQ:MSLE) by 391.6% during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor owned 491,624 shares of the company’s stock after acquiring an additional 391,624 shares during the period. Satellos Bioscience makes up approximately 0.0% of Stonepine Capital Management LLC’s holdings, making the stock its 16th largest holding. Stonepine Capital Management LLC owned about 2.36% of Satellos Bioscience worth $3,723,291 at the end of the most recent reporting period.

Satellos Bioscience Company Profile

Satellos Bioscience Corporation (NASDAQ:MSLE) is a biotechnology company focused on developing therapies that promote the natural regeneration and repair of skeletal muscle. Its research is based on the role of muscle stem cells, also known as satellite cells, in maintaining and rebuilding muscle tissue after injury or disease.

The company’s lead program is SAT-3247, an investigational small-molecule therapy being developed for muscle-wasting disorders, including Duchenne muscular dystrophy.